Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148707 · ClinicalTrials.gov registry record · Phase 2
Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00148707 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants.
The verdict
NCT00148707, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information on what effects (good or bad) CT-2103 (Xyotax) has on breast cancer as well as any side effects the drug may cause.
Interventions
- DRUG CT-2103 (Xyotax)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148707
The ClinicalTrials.gov registry entry for NCT00148707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CT-2103 (Xyotax) is the first listed.
NCT00148707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00148707 about?
NCT00148707 is a clinical study titled "Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer". The purpose of this study is to collect information on what effects (good or bad) CT-2103 (Xyotax) has on breast cancer as well as any side effects the drug may cause.
What is the current status of trial NCT00148707?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2004-10. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00148707?
The interventions under investigation include: CT-2103 (Xyotax) (DRUG).
Who is sponsoring clinical trial NCT00148707?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.